Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.

In this article we will dive into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed CATALYST PHARMACEUTICALS INC showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.

Why NASDAQ:CPRX may be interesting for canslim investors.

• The earnings per share (EPS) of CATALYST PHARMACEUTICALS INC have shown positive growth on a quarter-to-quarter (Q2Q) basis, with a 41.94% increase. This reflects the company's ability to improve its profitability over time.
• CATALYST PHARMACEUTICALS INC has achieved significant quarter-to-quarter (Q2Q) revenue growth of 28.26%, signaling its ability to capture market opportunities and drive top-line expansion. This growth underscores the company's effective execution and its potential for continued success.
• Over the past 3 years, CATALYST PHARMACEUTICALS INC has demonstrated 52.41% growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• With a favorable Return on Equity (ROE) of 22.52%, CATALYST PHARMACEUTICALS INC demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
• CATALYST PHARMACEUTICALS INC has maintained a healthy Relative Strength (RS) over the analyzed period, with a current 88.29 rating. This demonstrates the stock's ability to outperform its peers and indicates its competitive positioning. CATALYST PHARMACEUTICALS INC is well-positioned for potential price growth opportunities.
• With a Debt-to-Equity ratio at 0.0, CATALYST PHARMACEUTICALS INC showcases its prudent financial management. The company's balanced approach between debt and equity reflects its commitment to maintaining a stable capital structure.
• CATALYST PHARMACEUTICALS INC demonstrates a balanced ownership structure, with institutional shareholders at 83.75%. This indicates a diverse investor base, which can contribute to price stability and potential future growth.

Deciphering the Technical Picture of NASDAQ:CPRX

ChartMill assigns a proprietary Technical Rating to each stock. The score is computed daily by evaluating various technical indicators and properties. The score ranges from 0 to 10.

We assign a technical rating of 6 out of 10 to CPRX. CPRX was one of the better performers in the overall market, it is still ok in the medium term time frame, but very the very recent evolution is negative.

• The long term trend is positive and the short term trend is neutral. The long term trend may just continue or reversal may be around the corner!
• Looking at the yearly performance, CPRX did better than 88% of all other stocks.
• CPRX is part of the Biotechnology industry. There are 571 other stocks in this industry. CPRX outperforms 87% of them.
• CPRX is currently trading in the upper part of its 52 week range. The S&P500 Index is also trading in the upper part of its 52 week range, so CPRX is performing more or less in line with the market.
• In the last month CPRX has a been trading in the 20.46 - 23.74 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

Our latest full technical report of CPRX contains the most current technical analsysis.

What is the full fundamental picture of NASDAQ:CPRX telling us.

ChartMill employs a sophisticated system to assign a Fundamental Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple fundamental indicators and properties.

CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.

Our latest full fundamental report of CPRX contains the most current fundamental analsysis.

Our CANSLIM screen will find you more ideas suited for growth investing.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.